NCT05003700View on ClinicalTrials.gov

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 12, 2021

Primary Completion Date

May 26, 2023

Study Completion Date

July 4, 2024

Conditions

Hepatocellular Carcinoma

Interventions

PROCEDURE

Hepatic arterial infusion chemotherapy

administration of oxaliplatin and raltitrexed via the tumor feeding arteries every 3 weeks.

DRUG

Lenvatinib

8 mg once daily (QD) oral dosing.

DRUG

Camrelizumab

200mg intravenously every 3 weeks.

Trial Locations (1)

Unknown

Nanfang Hospital of Southern Medical University, Guangzhou

All Listed Sponsors

lead

Nanfang Hospital, Southern Medical University

OTHER

NCT05003700 - Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter